Science self-corrects: Cancer gene does not pass reproducibility test

February 12, 2018, Cold Spring Harbor Laboratory
The growth of human colon cancer cells (raised in culture) is unaffected by the MELK gene. Top row: untreated cells; bottom row: cells treated with a MELK inhibitor drug. Left two columns, control cells; right two columns, cells in which MELK gene has been knocked out. CSHL researchers conclude that MELK is not involved in cancer proliferation. Credit: Sheltzer Lab, CSHL

About 10 years ago, several labs discovered that a gene called MELK is overexpressed, or turned on to a high degree, in many cancer cell types. This evidence has prompted multiple ongoing clinical trials to test whether drugs that inhibit MELK can treat cancer in patients. Now, Cold Spring Harbor Laboratory (CSHL) researchers, led by CSHL Fellow Jason Sheltzer, report that MELK is not actually involved in cancer.

Furthermore, Sheltzer and his colleagues suggest that the discrepancy with previous findings results from inherent flaws in the scientific techniques that have been used to link MELK to cancer.

"Our study is a good illustration of the self-correcting nature of science," Sheltzer says.

Over the past few years, Sheltzer and Stony Brook University students Chris Giuliano and Ann Lin have been performing genomic analyses on tumors surgically removed from cancer patients. Their goal has been to identify whose activity levels are correlated with low patient survival rates. The researchers then planned to use a gene-editing technology called CRISPR to eliminate the genes from different cancer cell lines one at a time to see if they could kill the .

This is where MELK comes in. "Like other labs, we found that MELK tended to be very highly expressed in patients who did not survive very long," Sheltzer says.

Because so many previous studies using a variety of other methods had shown that MELK was essential for cancer cells, Sheltzer believed that his team could use the gene as a positive control in their CRISPR experiments. "We thought we would eliminate MELK and show that it killed cancer cells. Then we could know that our CRISPR techniques were working," Sheltzer says. "But, to our great surprise, the didn't die. They just didn't care."

The researchers then performed several experiments to ensure the CRISPR was working. "We eventually had to conclude that our technique was fine," Sheltzer says. "Rather, it was the previous findings about MELK's role in that were incorrect."

Sheltzer thinks some of the techniques have been prone to error due to what scientists call "off-target effects." One such technique, called RNA interference, harnesses a cellular mechanism controlling gene expression to switch off specific genes. "You think you're knocking down one gene, but in reality those techniques are not very specific, so you're also hitting a number of other different genes," Sheltzer says.

"We think that this might be a common problem," Sheltzer adds. "There are likely other genes like MELK out there and we're going to use CRISPR to find them."

Explore further: Role of melanoma-promoting protein revealed

More information: Giuliano, CJ et al, "MELK expression correlates with tumor mitotic activity but is not required for cancer growth," appeared online in eLife February 8, 2018.

Related Stories

Role of melanoma-promoting protein revealed

December 6, 2017
In a new study, Yale researchers describe the role of a protein that promotes growth of melanoma, the deadliest form of skin cancer.

Glioblastoma: Study ties three genes to radiation resistance in recurrent tumors

February 3, 2015
A new study identifies three genes that together enable a lethal form of brain cancer to recur and progress after radiation therapy.

Protein critical to early stages of cellular HIV infection identified

August 8, 2017
When a virus enters a cell, one of the first steps in the process of infecting that cell is removal of the protein coat that surrounds the virus's genetic material. The virus can then produce DNA from its own genes and insert ...

Relationship between incorrect chromosome number and cancer is reassessed after surprising experiments

January 12, 2017
Over a century ago, a German-born scientist experimenting with impregnated sea urchin eggs had an insight that led to one of the first modern theories of cancer. Theodor Boveri linked incorrect chromosome number in urchin ...

Versatile cancer drugs

December 1, 2017
Medications that block enzymes belonging to the kinase family are among the most effective pharmaceuticals for targeted cancer therapies. Scientists at the German Cancer Consortium (DKTK) at the Technical University of Munich ...

Recommended for you

10-year follow-up after negative colonoscopies linked to lower colorectal cancer risk

December 17, 2018
Ten years after a negative colonoscopy, Kaiser Permanente members had 46 percent lower risk of being diagnosed with and were 88 percent less likely to die from colorectal cancer compared with those who did not undergo colorectal ...

Survivors of childhood Hodgkin lymphoma face high long-term risk of solid cancers

December 17, 2018
New research refines existing evidence that survivors of childhood Hodgkin lymphoma face an elevated risk of developing various types of solid tumors many years later. In addition, certain subgroups of patients have an especially ...

Treatment shown to improve the odds against bone marrow cancer

December 15, 2018
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.